PROnostic Interest of 18F-FDG PET/CT in Patients With Metastatic Castration-resistant Prostate Cancer (mCPRC) Progressing

NCT06460454 | Completed

• 1 other identifier: 2024PI101
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this retrospective study was to assess the prognostic value of parameters extracted from 18FDG PET/CT and 68Ga-PSMA PET in the initial workup and follow-up of patients treated with 177Lu-PSMA in mCRPC.

Conditions

Prostate Cancer

Keywords

nuclear medicine; prostate cancer; PET scan

Outcome Measures

Primary Outcomes (1)

• Diagnostic accuracy of 18FDG PET metabolic volume

  Diagnostic accuracy of 18FDG PET metabolic volume in predicting 1-year overall survival.

  1 year

Secondary Outcomes (3)

• Diagnostic accuracy of 18FDG PET tumor parameter (SUVmax)

  1 year

• Diagnostic accuracy of 18FDG PET tumor parameters (SUVmean)

  1 year

• Diagnostic accuracy of 18FDG PET tumor parameters (FDG/PSMA mismatch)

  1 year

Study Arms (1)

Patients treated with 177Lu-PSMA for castration-resistant prostate cancer

Patients treated with 177Lu-PSMA for castration-resistant prostate cancer and who benefited from 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up.

Device: PET scan of 18F-FDG

Interventions

PET scan of 18F-FDG DEVICE

VEREOS PET scanner. Philips VEREOS digital PET-CT scanners are installed in the nuclear medicine department.

Patients treated with 177Lu-PSMA for castration-resistant prostate cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients treated with 177Lu-PSMA for castration-resistant prostate cancer at the CHRU de Nancy and who benefited from 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up.

You may qualify if:

• Patients treated with 177Lu-PSMA for castration-resistant prostate cancer at Nancy University Hospital
• Patients with 68Ga-PSMA and 18FDG PET scans as part of the initial workup and treatment follow-up

You may not qualify if:

• Patients who did not give their consent to use their data retrospectively

Sponsors & Collaborators

• Central Hospital, Nancy, France: lead

Study Sites (1)

Nuclear medicine Department CHRU de NANCY

Vandœuvre-lès-Nancy, 54511, France

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: June 11, 2024
• First Posted: June 14, 2024
• Study Start: November 1, 2024
• Primary Completion: January 1, 2025
• Study Completion: February 25, 2025
• Last Updated: March 4, 2025

Record last verified: 2025-02

Locations

FR (1)